What is HC Wainwright’s Forecast for ARWR FY2031 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at HC Wainwright issued their FY2031 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Thursday, October 15th. HC Wainwright analyst P. Trucchio forecasts that the biotechnology company will post earnings of $9.61 per share for the year. HC Wainwright currently has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.62) per share.

ARWR has been the subject of a number of other research reports. Citigroup began coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, September 8th. They issued a “buy” rating and a $108.00 price target for the company. B. Riley Financial increased their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. Chardan Capital restated a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday. Finally, UBS Group assumed coverage on Arrowhead Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $109.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $58.50 on Friday. Arrowhead Pharmaceuticals has a fifty-two week low of $36.57 and a fifty-two week high of $95.49. The stock’s 50-day moving average is $76.16 and its two-hundred day moving average is $76.00. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The firm has a market cap of $8.24 billion, a P/E ratio of -26.00 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.26) earnings per share.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth about $1,208,838,000. Baker BROS. Advisors LP lifted its position in shares of Arrowhead Pharmaceuticals by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock worth $144,441,000 after purchasing an additional 504,883 shares during the last quarter. Siren L.L.C. boosted its stake in Arrowhead Pharmaceuticals by 7.7% during the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after purchasing an additional 115,000 shares during the period. Janus Henderson Group PLC boosted its stake in Arrowhead Pharmaceuticals by 12.2% during the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after purchasing an additional 156,544 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in Arrowhead Pharmaceuticals by 23.8% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,273,266 shares of the biotechnology company’s stock valued at $79,612,000 after purchasing an additional 244,530 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Michael Perry sold 11,600 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.60% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Interim Phase 1/2a data showed ARO-MAPT crossed the blood-brain barrier and produced deep, durable tau reductions of up to 73% in healthy volunteers. Arrowhead said the results represent initial clinical validation of its TRiM™ CNS delivery platform, potentially expanding its ability to develop RNAi medicines for neurological diseases. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: Coverage of the Alzheimer’s results emphasized the potential breakthrough of delivering gene-silencing medicine into the brain, while follow-up commentary described the findings as unlocking a broader platform for central nervous system diseases. ARWR interim ARO-MAPT data
• Positive Sentiment: Analyst sentiment remains strongly bullish: UBS initiated coverage with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reaffirmed Buy ratings with targets of $115 and $120, respectively. These targets imply substantial potential upside if ARO-MAPT and the TRiM platform continue to progress. Arrowhead analyst ratings

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.